Archive for the ‘TapImmune Inc. TPIV’ Category

TapImmune, Inc. (TPIV.OB) Developing Therapeutic Cancer Vaccines

Monday, April 19th, 2010

TapImmune Inc. is a biotechnology company known for innovative approach of fighting cancer and other diseases through the use of preventative and therapeutic vaccines. The company’s program for a therapeutic vaccine to unspecific tumors represents a conceptual leap in the design of therapeutic cancer vaccines.

In pre-clinical studies, TapImmune’s AdhTAP vaccine has been shown to increase the sensitivity of the immune system to recognize and destroy cancerous cells. This result is achieved by resurrecting the expression of MHC class 1 restricted tumor antigens on the cell surface. The action of the immune system, specifically the killer T-cells, to recognize and destroy tumors is dependent on the expression of adequate numbers of MHC 1 molecules on the surface of the tumor.

The action of the company’s TAP vaccine increases MHC 1 expression by restoring the expression of TAP proteins in cancer, thereby increasing the transport of tumor antigens to the endoplasmic reticulum. Once there, the tumor antigen peptides can form functional MHC 1 molecules that will be transported and presented on the cancer cell surface to the immune system. In effect, the cancer will then be waving a big flag to the body’s immune system saying “Here I am, kill me.”

TapImmune’s vaccine re-establishes the presentation of tumor antigens on the MHC class 1 molecule, identifying the cancer to the cellular arm of the immune system. The killer T-cells of the immune system are stimulated to expand in number and destroy the cancerous cells. The expanded immune system response also provides a fabulous “bystander effect.” Tumors untouched by the vaccine also come under killer T-cell attack.

Let us hear your thoughts: TapImmune, Inc. Message Board

TapImmune, Inc. (TPIV.OB) Closes In On Magic Bullet Technology

Monday, April 12th, 2010

TapImmune Inc., a growing biotechnology company known for its innovative approach to fighting cancer and infectious diseases, is focused on a vaccine technology based on modulating the activity of the body’s own defense mechanisms to help it identify and fight off infected and/or cancerous cells.

Although the idea of assisting the body’s immune system is not new, TapImmune’s achievements have been especially encouraging. The company’s developments have been written up in a number of prestigious scientific journals, and have even broken through to the popular press with television and magazine coverage.

TapImmune’s primary product is the TAP vaccine, based on the TAP molecule, a remarkable formulation which has been found to play a key role in moving important cellular markers, called antigens, to the surface of cells. This is critical to immune system effectiveness and its ability to detect and attack malignant cells that develop into deadly metastatic cancers.

The immune system distinguishes between normal cells and cancerous or virus infected cells by monitoring the cell’s surface for a molecule and associated peptide fragments. When the cell presents this to the immune system, the body can determine the appropriate course of action. With normal healthy cells, this molecule is recognized and the cell is accepted by the body. However, if the cell’s surface contains abnormal peptide fragments, generated by viral proteins or cancerous mechanisms, the molecule stimulates the immune system’s army, called killer T-cells, to attack and destroy the cell.

It’s obviously critical that this antigen presentation process operates effectively to allow the immune system to differentiate bad cells from good cells. TapImmune’s vaccine technology successfully modulates the activity of this antigen processing machinery to significantly increase effective presentation of antigens to the immune system, where they can be evaluated and acted upon.

The TAP molecule also enhances targeted vaccines against infectious diseases. For example, in a smallpox vaccine study, potency was increased by 100-1000 times; impressive numbers, especially when considering that the global vaccine market is approaching $21 billion.

Let us hear your thoughts: TapImmune, Inc. Message Board

TapImmune, Inc. (TPIV.OB) Sees a Large Market Opportunity for Its TAP Vaccine Technology

Tuesday, April 6th, 2010

TapImmune Inc. is a biotech firm focused on increasing the efficacy of vaccines by enhancing antigen presentation through the use of the Transporter of Antigen Processing (TAP). The company’s technology has broad applications in developing therapeutic and preventative vaccines. TapImmune’s strategy is to build a patented proprietary product pipeline and capitalize on the breadth of the TAP technology through collaborative partnerships and license agreements.

The global vaccine market is estimated to be a $21 billion market in 2010. TapImmune sees large market opportunities for their TAP vaccine technology in the areas of prevention and treatment of infectious diseases and cancer.

Cancer is the second leading cause of death by illness in the United States. The market for cancer treatments in the United States has grown into a $10 billion market. This market is expected to continue increasing as, according to the National Cancer Institute, cancer will be the leading cause of death by illness in the US within 5 years. Cancer vaccines are expected to become a major player in the marketplace, with forecasts that it will become a $8 billion market by 2012.

Traditional approaches to cancer treatments include surgery, radiation therapy and chemotherapy. Because of the difficulty of removing or destroying all cancer cells, these approaches have numerous side effects for patients and a high mortality rate. TapImmune’s alternative to these approaches to cancer treatment is based on increased knowledge of the human genome and immune system.

Clinical studies to date have identified a large number of cancers deficient in TAP. TAP immunotherapy holds the potential of higher efficacy and lower side effects in cancer treatment. In pre-clinical trials for melanoma and lung carcinoma, animal survival rates of 70 percent were achieved using TAP immunotherapy and 100 percent survival when TAP was administered ex-vivo.

Many vaccines require the use of adjuvants to generate adequate protective immunity to prevent or treat infectious diseases. As a result, most vaccines are combined with an adjuvant that enhances the ability of an injected vaccine to stimulate an immune response and thus protect the recipient by preventing or treating diseases. TapImmune’s vaccine adjuvant has shown 100 times greater potency than non-adjuvanted vaccines in animal studies when combined with vaccines.

Currently, there is only one FDA-approved adjuvant available for use in humans. The need to immunize entire populations against a growing number of infectious diseases will require greater efficiency of the primary vaccine inoculae and may provide another lucrative opportunity for TapImmune.

Let us hear your thoughts: TapImmune, Inc. Message Board

TapImmune, Inc. (TPIV.OB) Provides Shareholders with a Corporate Update

Wednesday, March 31st, 2010

TapImmune Inc. is a company focused on increasing the efficacy of vaccines by enhancing antigen presentation through the use of the Transporter of Antigen Processing (TAP). Replacement of this transporter provides a significant immune response with the potential to treat a variety of cancers which lack normal amount of TAP.

The company is working on several significant products. TapImmune’s lead product candidate, AdhTAP, is designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The company is scheduled to move ahead with clinical manufacturing and toxicology studies for this cancer therapy.

TapImmune is also developing a TAP-based prophylactic vaccine which possibly may increase the efficacy of prophylactic vaccines against many pandemic infectious diseases by up to 1000 times. While the company’s current focus is on the use of TAP in vaccines, it is also focusing a significant effort on other disease modalities that can potentially benefit from the TAP platform.

The company recently provided a corporate update to their shareholders. The years of 2008 and 2009 were difficult for many companies, but TapImmune seems to have emerged stronger – raising $1 million in the capital markets – and better positioned to move forward.

TapImmune’s management stated that 2009 was a transformational year for the company. In the last quarter of 2009, TapImmune cemented its relationship with Netherlands-based Crucell (NASDAQ: CRXL). Crucell is a global biopharmaceutical company focused on research and development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Global drug giant Johnson & Johnson (NYSE: JNJ) owns 18 percent of Crucell.

The outbreak of pandemic diseases such as swine flu (H1N1) in 2009 and the constant threat of cancer has brought to the forefront the need for vaccines to both ameliorate as well as hopefully eliminate these diseases. Interest in the immunotherapy field was also stimulated last year by the development of Provenge for prostate cancer by Dendreon (NASDAQ: DNDN).

Over the last two years, TapImmune has been working diligently on finding suitable partners to form collaborative arrangements that will be mutually beneficial. One such arrangement announced on February 1, 2010 is with the Aeras Global TB Foundation. Aeras is one of the foremost non-profit organizations developing new approaches for tuberculosis (TB) vaccines. According to the World Health Organization, in 2007 there were 13.7 million active cases of tuberculosis, 9.3 million new cases and 1.8 million deaths from TB.

TapImmune and Aeras signed a letter of intent for research and development collaboration with an overall goal to evaluate the efficacy of TAP in concert with novel TB vaccine candidates. The company is expected to announce more such important partnerships in the future.

Let us hear your thoughts: TapImmune, Inc. Message Board

TapImmune, Inc. (TPIV.OB) to Collaborate with Aeras Global to Develop Tuberculosis Vaccine

Wednesday, March 24th, 2010

TapImmune Inc., biotech innovator and developer of therapies for infectious disease and oncology, and creator of the revolutionary TAP vaccine which has ability to restore antigen presentation in cells, announced in February of this year the signing of a letter of intent to begin a collaborative R&D campaign with Aeras Global TB Vaccine Foundation.

Aeras is dedicated to moving leading tuberculosis vaccines forward and making worldwide distribution and adoption of them ubiquitous despite age group or income level. Aeras operates under private foundations like The Bill & Melinda Gates Foundation, and accepts governmental aid as a non-profit product development partnership.

The focus of the aforementioned collaborative effort will be to demonstrate the viability of TPIV’s powerful TAP technology in supplementing new vaccines under development at Aeras. These new vaccines use TB encoded immunogens, with the pre-clinical work being handled at Aeras’ state-of-the-art Rockville, Maryland facility and the ultimate goal being clinical trials.

President of TPIV, Denis Corin, proudly hailed this bold venture with Aeras into the “next generation of vaccines”, which he sees (in the context of this collaboration) as providing the lofty but reachable goal of eliminating the global scourge of TB. Corin also made the point that TPIV’s unique TAP technology would play a key role in achieving that victory.

The vast technical expertise related to proprietary TAP1 and TAP2 provided by TPIV will prove to be instrumental in this new approach by Aeras, as the power of the TPIV technology (to act as a molecular adjuvant for enhancing precisely the sort of mechanisms on which this next-gen genetic vaccine depends) may prove to be the breakthrough consumers eagerly desire.

President and CEO of Aeras Global, Jerald C. Sadoff, MD, welcomed the opportunity to evaluate “TapImmune’s adjuvant technology” as a strong candidate for super-charging the next generation of TB vaccines currently under development.

TapImmune’s technology is an effective means of instantiating redundant systemic response, a very passive approach which allows the immune system to do its job and is ideally suited to the Aeras application, which utilizes over-expression of key antigens.

With over 1.8M deaths in 07 from TB, according to WHO data, and 13.7M cases overall, the global demand for an effective vaccine continues to promise a huge market, and if this collaboration strikes gold it is sure to evolve into a huge segment for TPIV.

Let us hear your thoughts: TapImmune, Inc. Message Board

TapImmune, Inc. (TPIV.OB) Video Chart for Wednesday, March 24, 2010

Wednesday, March 24th, 2010

TapImmune, Inc. is a low-float stock play that has a chart positioned to possibly reap some very nice gains. Technical analysis says to use support levels as entry points. Watch the video to see why TPIV is poised to move.

To view the video, please click the following link: http://www.qualitystocks.net/videocharts.php?chartvid_id=360

Let us hear your thoughts: TapImmune, Inc. Message Board

Beacon Equity Research Featured Company: TapImmune, Inc. (TPIV.OB)

Tuesday, February 23rd, 2010

TapImmune, Inc. is a biotechnology company focused on developing innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine, is a key component of a mechanism that moves characteristic markers called antigens to the surfaces of cells. Without TAP, there is a large reduction in presentation of cancer markers, making it impossible for the immune system to spot rogue cells and cancerous cells, allowing them to grow undetected.

The company’s vaccine has demonstrated its effectiveness in restoring TAP which in-turn restores and augments the characteristic marker (antigen) and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works to enhance targeted vaccines against infectious diseases. For example, including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1,000 times.

TapImmune’s technologies have broad applications in developing therapeutic and preventative vaccines. The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local news papers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens, among others.

Management believes that its cancer vaccine strategy is a unique therapeutic approach that addresses the problem of poor immune responses to cancer. Since restoring the TAP protein directs the body’s immune system to specifically target cancerous cells without damaging healthy tissue, this therapy potentially has a strong competitive advantage over other cancer therapies.

Let us hear your thoughts: TapImmune, Inc. Message Board

TapImmune, Inc. (TPIV.OB) ‘Tapping’ into Market for Therapeutic and Preventative Vaccines

Friday, December 11th, 2009

TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s TAP (transporters associated with antigen processing) technology has been featured in media outlets such ABC News, Business Week and Popular Mechanics as well as in many respected medical journals such as the Journal of Immunology.

The company’s lead product, the TAP vaccine, performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP – there are no cancer markers – so the body’s immune system fails to spot the rogue cells and the cancerous cells can grow undetected. TapImmune’s vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system.

The TAP molecule also works as an adjuvant to enhance targeted vaccines against infectious diseases. For example, including TAP in the studied smallpox vaccine showed potency was increased by 100 to 1,000 times.

TapImmune realizes that the potential for the global vaccine market is huge – a $21 billion market in 2010. The company’s strategy is to build a patented proprietary product pipeline through conducting pre-clinical vaccine programs and then moving successes on to human trials. Then the company will capitalize on the breadth of the TAP technology through collaborative partnerships and license agreements globally.

Let us hear your thoughts: TapImmune, Inc. Message Board

TapImmune, Inc. (TPIV.OB) – Magic Bullets

Tuesday, December 8th, 2009

Every day, more than 20,000 people die from some form of cancer worldwide. In the U.S., it’s approximately 1,500 deaths from cancer every day (more than 10 times the number of people that die in automobile accidents). Cancer is the second leading cause of death in the U.S., next to heart disease, accounting for nearly a quarter of all recorded deaths. There are many types of cancer, with each kind being more or less deadly than others. But, overall, if you do get cancer, there’s nearly a 50% chance that it will eventually take your life. The unique nature of the disease calls for what has been termed a magic bullet, something that can detect and hit only cells that are cancerous.

Although it is estimated that nearly a quarter of all cancers could be prevented by basic lifestyle changes, such as not smoking, eating a healthier diet (more fruits and vegetables), exercising, and generally maintaining a suitable weight, that still leaves over 400,000 cancer deaths in America alone believed unrelated to lifestyle.

Nevertheless, in spite of these grim statistics, there is more reason for optimism now than ever. That’s because scientists are learning how to work at the cellular and even molecular level in ways that were impossible before. This is critical, because cancer involves events at the micro sub-cellular level, making it difficult to attack with macro techniques.

The sub-cellular nature of cancer is emphasized by recent discoveries highlighting the role that genetics can play. For example, scientists have found that the absence of a single gene, called the GSTP gene, can increase the number of bowel tumors by a factor of 50. Other scientists have determined that certain naturally produced enzymes can have a dramatic effect on cancerous growths. Understanding the work of genes in cancer development can allow scientists to anticipate and treat various cancers before they become deadly, and such discoveries are now being made on a regular basis.

With heart disease, doctors can perform bypass surgery or provide other effective treatments that do not require manipulation of the inner workings of cells. With cancer, however, such approaches are a little like using an elephant gun to rid your house of ants. The real target is so small and elusive that good cells tend to get damaged or destroyed along with the bad. Although significant strides have been made to improve chemotherapy, radiation, and other macro treatments, progress against cancer has been frustratingly slow. Death rates are finally starting to decline, but scientists know now that the real achievements will be in the future, and probably the near future, as new technologies make it possible to deal with cancer on its own level. Rather than a single magic bullet, there will be many, operating in a carefully choreographed and highly focused attack on a particular cancer, including guiding assaults by the body’s own immune system.

TapImmune, Inc. (OTCBB: TPIV) is a good example of the new companies developing smart drugs to help the body identify and destroy cancerous cells. TapImmune’s vaccine technology is based upon helping individual cells better send up red flags whenever they become cancerous or infected with pathogens. This improved signaling allows the body’s immune system to destroy the cells before they become dangerous.

In addition to TapImmune, and giants like Pfizer (NYSE: PFE), there are a number of publicly traded companies focused on cancer research, drugs, and treatment, including:

• Abraxis Bio Science, Inc. (NASDAQ: ABII)
• Antigenics, Inc. (NASDAQ: AGEN)
• Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA)
• Infinity Pharmaceuticals, Inc. (NASDAZ: INFI)
• Northwest Biotherapeutics, Inc. (OTCBB: NWBO)
• Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)
• Lixte Biotechnology Holdings, Inc. (OTCBB: LIXT)
• Access Pharmaceuticals, Inc. (OTCBB: ACCP)
• Burzynski Research Institute (OTCBB: BZYR)
• Cel-Sci Corp. (NYSE Amex: CVM)

Let us hear your thoughts: TapImmune, Inc. Message Board

TapImmune, Inc. (TPIV.OB) Signs License Agreement with Crucell (CRXL)

Wednesday, December 2nd, 2009

TapImmune Inc., best known for developing immunotherapeutic vaccines for cancer and infectious diseases, announced recently that it has signed a license agreement with Crucell N.V. (NASDAQ: CRXL), a global biopharmaceutical company based in the Netherlands. The license allows TapImmune to use Crucell’s proprietary PER.C6® cells in its development programs.

The cell line is ideal for the development and large-scale production of a wide variety of biopharmaceuticals. Specifically, PER.C6 cells do not generate replication competent adenoviruses in the use of recombinant vaccines using adenoviral vectors, making it excellent for the production of adenoviral vectors for clinical applications. Generally, the PER.C6 cell line is the best documented line for vaccine development to date. Its extensive Biologics Master File at the U.S. FDA can be cross-referenced by licensees, resulting in simplification and acceleration of the IND filing and approval process.

The agreement is important for the production of TapImmune’s vaccine products. TapImmune’s primary product candidate, the AdhTAP vaccine enhancer, is designed to help the body’s immune system identify cancer cells so that it can destroy them. It does this by restoring and augmenting antigen presentation and subsequent recognition and killing of cancer cells by the immune system. TapImmune is currently planning for the commencement of clinical manufacturing and toxicology studies.

TapImmune is also developing a TAP based prophylactic vaccine, which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by as much as 1,000 times. As a vaccine, TAP technology could be significant in the fight against many pandemic infectious diseases. As a cancer therapy, TAP vaccine could prove to be a key component in a more successful assault on cancer.

The partnership between TapImmune and Crucell also gives Crucell the right to negotiate a license for TapImmune’s TAP technologies for infectious disease indications.

Let us hear your thoughts: TapImmune, Inc. Message Board

TapImmune, Inc. (TPIV.OB) Secures Additional Funding

Monday, November 30th, 2009

TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, announced last week that within the last 60 days the company secured an additional $600,000 in equity funding, bringing the total for the last six months of 2009 to over $1,000,000. The recent investors acquired $.80 units with each unit comprised of one share and one warrant exercisable at $1.20 for a period of 5 years.

The recent restructuring taken place at TapImmune has provided a more secure framework from which to pursue investment and industry partnerships. The company is dedicated to working diligently to secure additional funding and to move its product development and business forward.

Let us hear your thoughts: TapImmune, Inc. Message Board

TapImmune, Inc. (TPIV.OB) Among the Winners in the Booming Vaccine Business

Tuesday, November 24th, 2009

Recent headlines swirling around the swine flu have centered the focus of both the public and investors on vaccines and the vaccine industry. The vaccine marketplace is expected to show big gains through 2012 as it emerges as one of the most lucrative sectors of the global pharmaceutical industry. This bodes well for innovative companies such as TapImmune Inc. (OTCBB: TPIV).

TapImmune is a biotechnology company specializing in the development of cell-based vaccines and immunotherapeutics in the areas of oncology and infectious disease. The company’s vaccine technology is based on modulating the activity of the antigen processing machinery to increase effective presentation of antigens to the immune system. Transporters associated with antigen processing (TAP) play a major role in the antigen processing pathway.

One of the most lucrative areas for vaccine makers is vaccines which may treat various forms of cancer. The company’s lead product candidate, the AdhTAP vaccine enhancer, is designed to restore and augment presentation and subsequent recognition and killing of cancer cells by the immune system. As a stand-alone cancer therapy or in combination with other drugs, AdhTAP could prove to be a key component of a more successful assault on cancer. TapImmune is currently planning the development of AdhTAP for the commencement of clinical manufacturing and toxicology studies.

TapImmune is also developing a TAP-based prophylactic vaccine which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1,000 times. The company’s TAP technology could also enhance the creation of new vaccines in the fight against many pandemic infectious diseases.

Let us hear your thoughts: TapImmune, Inc. Message Board

TapImmune, Inc. (TPIV.OB) Announces QualityStocks Coverage

Monday, November 23rd, 2009

TapImmune, Inc. announced they will be featured in upcoming Daily Newsletters, Daily Blogs, and Message Boards. QualityStocks has over 750,000 subscribers to The Daily Stock Newsletter, which is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters and puts it all into one Free Daily Newsletter Report.

TapImmune, Inc. is focused on developing innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine, moves characteristic markers called antigens to the surfaces of cells. Without TAP, there is a large reduction in presentation of cancer markers, making it difficult for the immune system to spot rogue and cancerous cells, allowing them to grow undetected.

The company’s vaccine has demonstrated its effectiveness in restoring TAP which in-turn restores and augments the characteristic marker (antigen) and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works to enhance targeted vaccines against infectious diseases. For example, including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1,000 times.

Denis Corin, President of TapImmune, stated, “TapImmune has a unique and solid business foundation, and appreciates the opportunity to sponsor the QualityStocks Newsletter and Blogs. QualityStocks is providing a much needed service in the micro-cap and small-cap markets.”

Let us hear your thoughts: TapImmune, Inc. Message Board

TapImmune, Inc. (TPIV.OB) is “One to Watch”

Friday, November 20th, 2009

TapImmune, Inc. is a biotechnology company focused on developing innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine, is a key component of a mechanism that moves characteristic markers called antigens to the surfaces of cells. Without TAP, there is a large reduction in presentation of cancer markers, making it impossible for the immune system to spot rogue cells and cancerous cells, allowing them to grow undetected.

The company’s vaccine has demonstrated its effectiveness in restoring TAP which in-turn restores and augments the characteristic marker (antigen) and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works to enhance targeted vaccines against infectious diseases. For example, including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1,000 times.

TapImmune’s technologies have broad applications in developing therapeutic and preventative vaccines. The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local news papers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens, among others.

Management believes that its cancer vaccine strategy is a unique therapeutic approach that addresses the problem of poor immune responses to cancer. Since restoring the TAP protein directs the body’s immune system to specifically target cancerous cells without damaging healthy tissue, this therapy potentially has a strong competitive advantage over other cancer therapies.

Let us hear your thoughts: TapImmune, Inc. Message Board